ASCO 2024 | Gut microbiome and treatment outcomes in HR+/HER2- breast cancer
Alexis LeVee
• 2 Jun 2024
Alexis LeVee, MD, City of Hope, Duarte, CA, comments on the utility of stool microbial profiling in a Phase I/II study (NCT02778685), which assessed palbociclib, pembrolizumab, and endocrine therapy (ET) in patients with HR+/HER2- metastatic breast cancer (MBC). Gut microbiome profiling suggests specific bacterial taxa and metabolic pathways are associated with treatment response, indicating a potential biomarker for immune checkpoint inhibitor efficacy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
